Oncimmune to Present at 2019 CBIIC

RNS Number : 6704M

Oncimmune Holdings PLC

18 September 2019

 

18 September 2019

Oncimmune Holdings plc

("Oncimmune" or the "Company")

Oncimmune to Present at 2019 China BioMed Innovation and Investment Conference in Suzhou, China

Oncimmune Holdings plc (AIM: ONC.L), a Leading Global Immunodiagnostics Group, will be keynoting the China BioMed Innovation and Investment Conference (CBIIC) on Sunday 22^nd September 2019, at 9:00 am CST (2:00 am BST) in Suzhou, China.

The Company's presentation will be made available under the IR section on Oncimmune's website on Monday 23^rd September 2019.

Adam Hill, Chief Executive Officer of Oncimmune, will be presenting an overview of Oncimmune, including progress in delivering the forward strategy.  He will be available to take questions following the event.

-Ends-

For further information:

Oncimmune Holdings plc

Cléa Rosenfeld, Head of Investor Relations

[e-mail]

Media enquiries:

FTI Consulting

Brett Pollard, Andrew Ward

[e-mail]

[phone]

About CBIIC

CBIIC was established in 2016 and initiated by China Pharmaceutical Innovation and Research Development Association (PhIRDA). CBIIC aims to promotes the communication between the pharmaceutical industry and the investment community in order to facilitate innovation in unmet clinical needs. To that end, CBIIC holds an annual investor conference and this year around 3500 participants are expected to attend.

About Oncimmune

Beating cancer, one test at a time

The battle against cancer hinges on early detection and then the delivery of effective treatment. Oncimmune is working to revolutionise both the detection of cancer and its treatment by harnessing the sophisticated disease detecting capabilities of the immune system to find cancer in its early stages. Our range of diagnostic tests assist clinicians to identify the presence of cancer four years or more before standard clinical diagnosis, whilst our technology platform and sample biobanks are helping healthcare companies to develop new cancer treatments.

Oncimmune was founded in 2002 and launched its platform technology in 2009, followed by its first commercial tests, EarlyCDT^® Lung and EarlyCDT Liver. To date, over 155,000 tests have been performed for patients worldwide. EarlyCDT Lung was also used in what is believed to be the largest randomised controlled study for the early detection of lung cancer using biomarkers, the successful National Health Service (NHS) ECLS study of 12,209 high-risk smokers in Scotland which demonstrated EarlyCDT Lung reduced the incidence of patients with late-stage lung cancer or unclassified presentation at diagnosis, compared to standard clinical practice.

Oncimmune, headquartered at its laboratory facility in Nottingham, UK, has a discovery research centre in Dortmund, Germany and a CLIA lab in Kansas, US as well as an office in London, UK and a partner representative office in Shanghai, China. Oncimmune joined the Alternative Investment Market (AIM) of the London Stock Exchange in May 2016 under the ticker ONC.L.

What is EarlyCDT Lung?

A blood test using a panel of seven immunogenic proteins for the testing of tumour-related antibodies specific to lung cancer.

For more information, visit www.oncimmune.com

 

END

 

 

NRALLFSEAEIDLIA